Universal Vision Biotechnology Co., Ltd.TPEX: 3218

Announcement of 2Q2022 consolidated financial reports approved by the Board of Directors

· Issued by Universal Vision Biotechnology Co., Ltd.
Close
Today's Information

Provided by: UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
SEQ_NO 1 Date of announcement 2022/08/11 Time of announcement 17:07:20
Subject
 Announcement of 2Q2022 consolidated financial
reports approved by the Board of Directors
Date of events 2022/08/11 To which item it meets paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/11
2.Date of the audit committee approved:2022/08/11
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2022/1/1~2022/6/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):1,624,875
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):992,612
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):507,701
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD): 514,131
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):408,776
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):400,388
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):5.26
11.Total assets end of the period (thousand NTD):4,017,890
12.Total liabilities end of the period
(thousand NTD):1,651,641
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,215,090
14.Any other matters that need to be specified:N/A

Company analysis

Earlier from Universal Vision Biotechnology

All Universal Vision Biotechnology news releases